Quidel Corp. Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne & Friends’ Virtual Concert ...
October 22 2020 - 8:00AM
Business Wire
As part of its commitment to help educate Americans on the
perils of Lyme disease, Quidel Corporation announced today that it
will be one of the sponsors of the inaugural Global Lyme Alliance
(GLA) “#FightLyme With Avril Lavigne & Friends” concert being
held on Oct. 24. Quidel is the diagnostic health care manufacturer
behind the industry’s most rapid and reliable in-office test for
Lyme disease, the Sofia 2 Lyme FIA test.
“The Global Lyme Alliance has been a passionate and important
partner for Quidel in our fight against Lyme disease,” said Judi
Tilghman, Ph.D., vice president of technology assessment at Quidel.
“Over the years they have helped fund the most urgent and promising
research in the field, while expanding education and awareness
programs for the general public and physicians. We’re honored to be
their partner for this wonderful upcoming event.”
Being held in lieu of its annual gala, GLA will be presenting
the inaugural #FightLyme With Avril & Friends virtual concert
featuring Avril Lavigne, Rob Thomas, OneRepublic, Alessia Cara and
host Wilmer Valderrama. The concert is designed to raise awareness
and funds for GLA and The Avril Lavigne Foundation in support of
their fight to conquer Lyme disease and other tick-borne diseases
through research, education, awareness and patient services. Both
Lavigne and Thomas have experienced Lyme disease on a personal
level, and Lavigne is also a GLA board member who has been
extremely vocal about the fight against Lyme disease.
The Oct. 24 concert will begin at 8 p.m. Eastern Time. Tickets
can be purchased and more information is available at
https://tinyurl.com/y54dn89a. More information on the Global Lyme
Alliance can be found at GLA.org.
Lyme disease afflicts as many as 400,000 Americans every year
and can lead to a number of serious, life-threatening problems if
not caught early. Leading the way in Lyme disease testing is
Quidel’s innovative Sofia® 2 Lyme FIA test. This test provides a
patient as well as his or her physician with indicative results
within minutes as opposed to days, which has historically been the
norm. Performed in the privacy of a doctor’s office or local
clinic, it is also the only test that can get results from a simple
finger prick of blood. Given that the vast majority of patients
tested are negative, not having to wait days for test results
allows physicians and nurse practitioners to more rapidly treat
those patients with positive results while more quickly pursuing
other diagnosis and treatment for those who test negative.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care delivering a continuum of
rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201022005508/en/
Jim Yeager 424.644.0225 (office) 818.264.6812 (mobile)
jim@breakwhitelight.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Sep 2023 to Sep 2024